IRCT20230114057122N1已完成3 期
Effect of Empagliflozin and Topiramate co-administration on anthropometric indices and metabolic markers in individuals with excess weight on a calorie restricted diet
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Men and women over 18 years of age; with body mass index 30-40 kg/m2 with or without hypertension and/or dislipidemia, or body mass index 27-30 kg/m2 with hypertension and/or dislipidemia; without diabetes or eating disorders; not taking vitamin and mineral supplements; not being pregnant or breastfeeding.
排除标准
- •Any type of acute illness during the study; not comply with intervention or diet (less than 80% compliance)
研究者
相似试验
已完成
不适用
Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of ObesityObesityNCT04043702Ministry of Health and Population, Egypt200
已完成
Unknown
Evaluation of the effect of empagliflozin in combination with pioglitazone on fatty liver diseaseFatty liver.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20240208060939N1Artesh University of Medical Sciences80
尚未招募
3 期
Effect of Empagliflozin as adjunctive therapy versus placebo on serum level of oxidative stress biomarkers in diabetic patients with systolic heart failureIRCT20120215009014N484Hamedan University of Medical Sciences80
尚未招募
2 期
Comparing the effect of Empagliflozin, Pioglitazone and their combination, on the course of non-alcoholic fatty liver disease in diabetic patientson-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20230903059343N1Arak University of Medical Sciences120
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90